SecBot SecBot
8-K ·Filed Jun 4, 2026

ABEO

ABEONA THERAPEUTICS INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago SEC0001493152-26-027197
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for official FDA meeting minutes and any updates on ABO-701 preclinical data. The 2027 IND timeline is unchanged and provides no near-term catalyst. Stock movement likely limited until concrete regulatory milestones are achieved.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.82
T+0 close · Jun 4, 2026 · via day close
Latest settled
+1.72%
T+60 · $5.92
Vs SPY
−0.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $5.82entry
  2. T+1 · 6mo ago −6.19%α −3.59% · $5.46
  3. T+5 · 5mo ago −4.98%α −2.43% · $5.53
  4. T+20 · 4mo ago +9.97%α +11.34% · $6.40
  5. T+60 · 3mo ago +1.72%α −0.16% · $5.92

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abeona Therapeutics reported a constructive pre-IND meeting with the FDA regarding ABO-701, a novel T-cell therapy for prostate cancer. The company reaffirms its target to submit an IND application in 2027, but official FDA minutes are pending and no assurance of acceptance was given.

Key Facts

  • Pre-IND meeting with FDA held on June 3, 2026 for ABO-701 (PSMA-targeted T-cell therapy for prostate cancer)
  • Company believes meeting was constructive; official FDA minutes not yet received
  • IND submission target remains 2027, consistent with prior timeline
  • No financial figures, deal values, or clinical data disclosed in the filing

Financial Impact

No financial impact disclosed; pre-revenue clinical-stage company with no near-term revenue from ABO-701

Risk Factors

  • FDA may require additional preclinical studies or data before accepting IND
  • IND may not be accepted or may be delayed beyond 2027
  • No assurance of clinical trial authorization or eventual approval

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-027197
Document: 0001493152-26-027197-index-headers.html0001493152-26-027197
Document: 0001493152-26-027197-index.html0001493152-26-027197
Document: 0001493152-26-027197.txt0001493152-26-027197

Track record

29 reports on ABEO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  5. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
  6. Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  7. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
  8. Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
  9. Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
  10. Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026